Format

Send to

Choose Destination
ERJ Open Res. 2018 Dec 3;4(4). pii: 00085-2018. doi: 10.1183/23120541.00085-2018. eCollection 2018 Oct.

Patients' perspective on pulmonary rehabilitation: experiences of European and American individuals with chronic respiratory diseases.

Author information

1
Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, USA.
2
VA Connecticut Healthcare System, West Haven, CT, USA.
3
Both authors contributed equally.
4
National and Kapodistrian University of Athens, Faculty of Physical Education and Sports Sciences, Athens, Greece.
5
Dept of Sport, Exercise and Rehabilitation, School of Health and Life Sciences, Northumbria University Newcastle, Newcastle Upon Tyne, UK.
6
European Lung Foundation, Sheffield, UK.
7
Dept of Research and Education, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands.
8
Dept of Respiratory Medicine, Maastricht University Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands.
9
REVAL - Rehabilitation Research Center, BIOMED - Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.

Abstract

Pulmonary rehabilitation benefits people with chronic respiratory diseases, yet few eligible patients enrol. People with chronic lung diseases are often unaware of or lack access to PR. This is an important healthcare disparity that should be addressed. http://ow.ly/2HER30mxLLj.

Conflict of interest statement

Conflict of interest: Carolyn L. Rochester has served on scientific advisory boards for COPD for Glaxo-Smith Kline, Inc, and Boehringer Ingelheim Pharmaceuticals, Inc. She has participated in COPD-related clinical trials sponsored by GSK and Astra-Zeneca Pharmaceuticals, Inc. Carolyn L. Rochester co-chaired the ATS-ERS joint task force on policy in pulmonary rehabilitation, and from 2015–2017 served as the chair of the ATS Assembly on pulmonary rehabilitation. She does not believe any of the above represent conflicts of interest in regard to the currently submitted research letter. Conflict of interest: I. Vogiatzis has nothing to disclose. Conflict of interest: P. Powell is an employee of the European Lung Foundation. Conflict of interest: S. Masefield was an employee of the European Lung Foundation at the time of writing. Conflict of interest: M.A. Spruit reports personal fees from Boehringer Ingelheim, GSK and AstraZeneca, and grants from Netherlands Lung Foundation, outside the submitted work.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center